The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Isatuximab plus pomalidomide and dexamethasone in RRMM with 1q21 gain
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy of isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) and 1q21 gain, based on an analysis of the ICARIA-MM (NCT02990338) trial. The findings indicate the efficacy of this combination for this high-risk group. It appears more effective than combinations involving daratumumab, which Dr Richardson suggests may be due to daratumumab’s reliance on complement-mediated killing, and 1q amplification is associated with greater resistance to this mechanism. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda, Oncopeptides, Celgene/BMS, Karyopharm, Takeda.
